Bank Of Montreal Xencor Inc Transaction History

Bank Of Montreal

$197 Billion
Q2 2024

A detailed history of Bank Of Montreal transactions in Xencor Inc stock. As of the latest transaction made, Bank Of Montreal holds 8,883 shares of XNCR stock, worth $179,880. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,883

Holding current value

$179,880

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$18.21 - $24.5 $161,759 - $217,633	8,883 New	8,883 $168,000
Q2 2023 Aug 02, 2023	BUY	$24.77 - $29.9 $7,530 - $9,089	304 Added 4.1%	7,713 $192,000
Q1 2023 Jun 13, 2024	BUY	$25.95 - $36.95 $238,843 - $340,087	9,204 New	9,204 $256,000
Q4 2022 Feb 01, 2023	BUY	$24.79 - $30.86 $183,669 - $228,641	7,409 New	7,409 $192,000
Q2 2022 Aug 11, 2022	SELL	$19.74 - $29.01 $349,220 - $513,215	-17,691 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$26.68 - $41.63 $9,871 - $15,403	-370 Reduced 2.05%	17,691 $488,000
Q4 2021 Feb 11, 2022	SELL	$33.67 - $43.44 $1.09 Million - $1.41 Million	-32,450 Reduced 64.24%	18,061 $737,000
Q3 2021 Nov 12, 2021	BUY	$30.65 - $35.68 $8,612 - $10,026	281 Added 0.56%	50,511 $1.72 Million
Q2 2021 Aug 12, 2021	BUY	$34.33 - $44.68 $1.72 Million - $2.24 Million	50,230 New	50,230 $1.77 Million

Others Institutions Holding XNCR

# of Institutions

204

Shares Held

63.1M

Call Options Held

3.9K

Put Options Held

Black Rock Inc. New York, NY

11.1M
Shares

$225 Million
0.0% of portfolio
Primecap Management CO Pasadena, CA

9.12M
Shares

$185 Million
0.13% of portfolio
Vanguard Group Inc Valley Forge, PA

7M
Shares

$142 Million
0.0% of portfolio
Eco R1 Capital, LLC San Francisco, CA

5.33M
Shares

$108 Million
3.57% of portfolio
Price T Rowe Associates Inc Baltimore, MD

3.96M
Shares

$80.2 Million
0.01% of portfolio

View Full List

About Xencor Inc

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.21B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

More about XNCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.

Account